At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
Halobetasol Topical Foamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol Propionate Foam, 0.05% in Subjects 12 to Less Than 18 Years of Age With Plaque Psoriasis Receiving Two Weeks of Treatment
In Brief
A Phase 4 clinical trial evaluating Halobetasol Topical Foam for Plaque Psoriasis. Completed, enrolled 24 participants across 11 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate Halobetasol Propionate (HBP) foam, 0.05% in subjects aged 12 through less than 18 years with plaque psoriasis in order to check the safety, the potential to suppress the adrenal glands and the degree to which the drug is absorbed into the bloodstream.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesGeorgia, Poland, Ukraine, United States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
Enrollment StartJun 2019
First PostedJun 2019
Primary CompletionDec 2019
TodayJul 2026
First PostedJun 20, 2019
Enrollment StartJun 14, 2019
Primary CompletionDec 30, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.0 years ago
Interventions
Halobetasol Topical Foamdrug
Foam